NASDAQ:BPTS

Biophytis Competitors

$10.70
+0.06 (+0.56 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.70
$11.20
50-Day Range
$10.20
$15.00
52-Week Range
$10.20
$18.50
Volume2,608 shs
Average Volume12,296 shs
Market Capitalization$121.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Biophytis (NASDAQ:BPTS) Vs. VKTX, NBRV, TXMD, MTEM, AKUS, and SIGA

Should you be buying BPTS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Biophytis, including Viking Therapeutics (VKTX), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Molecular Templates (MTEM), Akouos (AKUS), and SIGA Technologies (SIGA).

Viking Therapeutics (NASDAQ:VKTX) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Viking Therapeutics and Biophytis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viking TherapeuticsN/A-17.58%-16.83%
BiophytisN/AN/AN/A

Institutional and Insider Ownership

52.6% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 2.6% of Biophytis shares are owned by institutional investors. 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Viking Therapeutics and Biophytis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A$-39,490,000.00($0.54)-11.31
BiophytisN/AN/A$-19,480,000.00N/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Viking Therapeutics and Biophytis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viking Therapeutics00903.00
Biophytis0000N/A

Viking Therapeutics presently has a consensus target price of $15.3750, suggesting a potential upside of 151.64%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Biophytis.

Summary

Viking Therapeutics beats Biophytis on 4 of the 7 factors compared between the two stocks.

Nabriva Therapeutics (NASDAQ:NBRV) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nabriva Therapeutics and Biophytis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nabriva Therapeutics01102.50
Biophytis0000N/A

Nabriva Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 347.76%. Given Nabriva Therapeutics' higher possible upside, equities research analysts plainly believe Nabriva Therapeutics is more favorable than Biophytis.

Valuation & Earnings

This table compares Nabriva Therapeutics and Biophytis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nabriva Therapeutics$5.03 million94.36$-69,480,000.00($5.20)-0.26
BiophytisN/AN/A$-19,480,000.00N/AN/A

Biophytis has lower revenue, but higher earnings than Nabriva Therapeutics.

Institutional & Insider Ownership

0.9% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 2.6% of Biophytis shares are held by institutional investors. 2.8% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Nabriva Therapeutics and Biophytis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nabriva Therapeutics-506.93%-81.28%-52.84%
BiophytisN/AN/AN/A

Summary

Biophytis beats Nabriva Therapeutics on 5 of the 9 factors compared between the two stocks.

TherapeuticsMD (NASDAQ:TXMD) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

44.3% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 2.6% of Biophytis shares are owned by institutional investors. 8.8% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares TherapeuticsMD and Biophytis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-229.09%N/A-77.22%
BiophytisN/AN/AN/A

Earnings & Valuation

This table compares TherapeuticsMD and Biophytis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$64.87 million7.27$-183,520,000.00($0.68)-1.76
BiophytisN/AN/A$-19,480,000.00N/AN/A

Biophytis has lower revenue, but higher earnings than TherapeuticsMD.

Analyst Recommendations

This is a breakdown of recent recommendations for TherapeuticsMD and Biophytis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD10302.50
Biophytis0000N/A

TherapeuticsMD currently has a consensus price target of $5.0667, suggesting a potential upside of 322.22%. Given TherapeuticsMD's higher possible upside, equities research analysts clearly believe TherapeuticsMD is more favorable than Biophytis.

Summary

TherapeuticsMD beats Biophytis on 5 of the 8 factors compared between the two stocks.

Biophytis (NASDAQ:BPTS) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Biophytis and Molecular Templates, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biophytis0000N/A
Molecular Templates01302.75

Molecular Templates has a consensus target price of $14.50, indicating a potential upside of 72.82%. Given Molecular Templates' higher possible upside, analysts plainly believe Molecular Templates is more favorable than Biophytis.

Profitability

This table compares Biophytis and Molecular Templates' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiophytisN/AN/AN/A
Molecular Templates-611.90%-138.03%-60.44%

Earnings & Valuation

This table compares Biophytis and Molecular Templates' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A$-19,480,000.00N/AN/A
Molecular Templates$18.84 million24.98$-104,920,000.00($2.13)-3.94

Biophytis has higher earnings, but lower revenue than Molecular Templates.

Insider and Institutional Ownership

2.6% of Biophytis shares are owned by institutional investors. Comparatively, 63.0% of Molecular Templates shares are owned by institutional investors. 27.5% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Molecular Templates beats Biophytis on 5 of the 9 factors compared between the two stocks.

Biophytis (NASDAQ:BPTS) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biophytis and Akouos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biophytis0000N/A
Akouos01402.80

Akouos has a consensus target price of $30.00, indicating a potential upside of 120.59%. Given Akouos' higher possible upside, analysts plainly believe Akouos is more favorable than Biophytis.

Earnings & Valuation

This table compares Biophytis and Akouos' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A$-19,480,000.00N/AN/A
AkouosN/AN/A$-48,600,000.00($2.77)-4.91

Profitability

This table compares Biophytis and Akouos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiophytisN/AN/AN/A
AkouosN/A-17.21%-16.05%

Insider & Institutional Ownership

2.6% of Biophytis shares are owned by institutional investors. Comparatively, 96.1% of Akouos shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biophytis (NASDAQ:BPTS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Biophytis and SIGA Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A$-19,480,000.00N/AN/A
SIGA Technologies$124.96 million3.71$56.34 million$0.777.92

SIGA Technologies has higher revenue and earnings than Biophytis.

Profitability

This table compares Biophytis and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiophytisN/AN/AN/A
SIGA Technologies50.59%56.02%46.77%

Analyst Recommendations

This is a summary of current recommendations for Biophytis and SIGA Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biophytis0000N/A
SIGA Technologies0000N/A

Institutional and Insider Ownership

2.6% of Biophytis shares are held by institutional investors. Comparatively, 26.8% of SIGA Technologies shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

SIGA Technologies beats Biophytis on 7 of the 7 factors compared between the two stocks.


Biophytis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.9$6.11+0.7%$477.19 millionN/A-10.18Analyst Report
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.34+0.7%$474.62 million$5.03 million-0.63
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.20+0.8%$471.83 million$64.87 million-2.11News Coverage
Molecular Templates logo
MTEM
Molecular Templates
1.7$8.39+0.7%$470.64 million$18.84 million-3.76Analyst Downgrade
Akouos logo
AKUS
Akouos
1.6$13.60+1.2%$468.51 millionN/A-1.06News Coverage
SIGA Technologies logo
SIGA
SIGA Technologies
0.4$6.10+3.0%$464.00 million$124.96 million7.53
MedAvail logo
MDVL
MedAvail
1.8$14.03+0.2%$456.27 million$13.97 million-5.23
Athenex logo
ATNX
Athenex
1.6$4.84+2.5%$452.60 million$144.39 million-2.78
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.17+0.9%$448.12 millionN/A-4.52
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.8$8.93+0.8%$445.98 million$85.55 million-4.00
BeyondSpring logo
BYSI
BeyondSpring
1.3$11.16+0.7%$436.83 million$180,000.00-5.47Analyst Revision
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.5$6.68+3.7%$434.27 million$100.36 million-5.43Insider Selling
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$7.36+0.5%$430.47 million$22.33 million-56.62
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.4$14.45+1.5%$428.66 million$9.33 million-4.74
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.4$14.08+1.6%$425.61 million$2.71 million-22.71News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.5$11.81+0.9%$423.71 million$58.12 million0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.7$9.98+0.1%$422.61 million$25 million-13.31
Kindred Biosciences logo
KIN
Kindred Biosciences
1.4$9.21+0.1%$416.97 million$42.16 million-40.04
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$11.13+6.1%$412.85 million$120,000.000.00
HOWL
Werewolf Therapeutics
2.2$14.87+0.4%$409.94 millionN/A0.00
KemPharm logo
KMPH
KemPharm
1.2$14.30+1.5%$407.65 million$13.29 million-4.77
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.7$32.88+0.9%$406.56 million$208.48 million-25.69
Homology Medicines logo
FIXX
Homology Medicines
1.4$7.11+1.7%$405.87 million$2.70 million-3.49
Cue Biopharma logo
CUE
Cue Biopharma
1.2$12.83+4.6%$403.03 million$3.15 million-8.55Gap Up
Inozyme Pharma logo
INZY
Inozyme Pharma
1.6$17.12+5.8%$402.03 millionN/A-3.35
Oncorus logo
ONCR
Oncorus
1.9$15.45+1.9%$396.29 millionN/A-1.65
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$13.28+1.9%$393.93 million$2.88 million-2.45
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.72+0.9%$392.32 million$225.10 million-14.09
Verona Pharma logo
VRNA
Verona Pharma
1.6$6.62+1.7%$383.53 millionN/A-2.98
DURECT logo
DRRX
DURECT
1.6$1.68+0.6%$382.04 million$30.11 million-168.00News Coverage
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.5$5.91+3.4%$382.03 million$6.36 million-3.02
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.7$10.24+0.7%$377.30 million$430,000.000.00
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$18.85+1.0%$376.00 million$385.20 million16.83
89bio logo
ETNB
89bio
2.0$18.67+1.8%$374.52 millionN/A-6.06
MEI Pharma logo
MEIP
MEI Pharma
1.6$3.32+1.5%$373.81 million$28.91 million-4.49
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$14.75+2.7%$370.42 millionN/A-0.14
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.7$1.12+0.9%$368.77 millionN/A-2.29
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.6$2.57+1.9%$368.38 millionN/A-8.03
GXGX
GX Acquisition
1.9$10.19+0.0%$366.20 millionN/A0.00
Theratechnologies logo
THTX
Theratechnologies
1.2$3.86+1.6%$365.60 million$66.05 million-12.45News Coverage
XOMA logo
XOMA
XOMA
1.5$31.99+4.0%$360.53 million$29.39 million168.37News Coverage
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
0.7$2.01+0.5%$360.07 million$40,000.00-0.81
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$3.65+3.6%$355.21 million$45.60 million-6.52Analyst Revision
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.7$7.06+4.5%$354.45 million$10.80 million-6.66
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.6$3.58+0.3%$352.82 million$156.47 million14.32
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$7.04+4.1%$350.99 million$20.08 million-2.03
UroGen Pharma logo
URGN
UroGen Pharma
1.9$16.76+1.8%$350.23 million$11.80 million-3.16News Coverage
Cerecor logo
CERC
Cerecor
1.9$3.65+4.1%$348.47 million$6.70 million-6.40
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.4$10.08+4.4%$344.93 million$36.98 million-8.06
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.4$7.29+3.8%$342.11 million$46.92 million-3.80Analyst Report
Analyst Revision
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.